Conference - Lisbon, Portugal
Main Topics:
• The role of microRNAs and circulating tumor cells in ABC
• Intratumour heterogeneity in ABC
• Patient xenograph models
• New drugs, new side-effects: Endocrine, pulmonary and immunologic alterations
• How to best assess efficacy of therapies in ABC (new endpoints, innovative trial designs)
• The role of PI3K in ABC
• Cdk inhibitors for ER+ ABC
• Immune-based therapies for management of ABC
• The role of androgen receptor and its modulators in ABC
• Optimal sequence of cytotoxic and endocrine agents
• Until when should ABC be treated? (maximum response, progression, how many lines are acceptable?)
• Surgery of the primary in stage IV at diagnosis: What's new?
• Advances in supportive and palliative care
• The programme will include patient advocacy sessions developed in cooperation with several leading breast cancer patient advocacy groups worldwide.
- Organization: European School of Oncology (ESO) Via Turati, 29 20121 Milano, Italy
Thu, Nov 05, 2015 - Sat, Nov 07, 2015
CCL - Centro de Congressos de Lisboa
Praça das Industrias, Lisbon, Portugal
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.